# Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting
Canonical URL: https://biopharmsignal.com/news/CABA/cabaletta-bio-presents-preconditioning-free-clinical-data-and-automated-manufacturing-translational-data-for-rese-cel-at-asgct-2026-annual-meeting
Ticker: CABA
Company: Cabaletta Bio
Source: Cabaletta Bio
Published: 2026-05-14 11:00 EST
Original Source URL: https://www.cabalettabio.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-06-03 11:00 EST — [Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress](https://biopharmsignal.com/news/CABA/cabaletta-bio-announces-new-rese-cel-data-and-development-updates-across-autoimmune-portfolio-including-encouraging-early-pc-free-lupus-findings-at-eular-2026-congress) — Source: Cabaletta Bio
- 2026-05-14 11:05 EST — [Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/CABA/cabaletta-bio-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: Cabaletta Bio
- 2026-05-14 11:00 EST — [Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting](https://biopharmsignal.com/news/CABA/cabaletta-bio-presents-preconditioning-free-clinical-data-and-automated-manufacturing-translational-data-for-rese-cel-at-asgct-2026-annual-meeting) — Source: Cabaletta Bio
- 2026-05-04 10:35 EST — [Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering](https://biopharmsignal.com/news/CABA/cabaletta-bio-announces-pricing-of-150-million-underwritten-offering) — Source: Cabaletta Bio
- 2026-04-28 12:00 EST — [Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel](https://biopharmsignal.com/news/CABA/cabaletta-bio-and-cellares-announce-10-year-commercial-supply-agreement-for-rese-cel) — Source: Cabaletta Bio
## Related News
- 2026-07-22 20:15 EST — BFRG — [BullFrog AI to Participate in the BTIG Virtual Biotechnology Conference](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-the-btig-virtual-biotechnology-conference-5880a10e)
- 2026-07-22 20:05 EST — AZTA — [Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast](https://biopharmsignal.com/news/AZTA/azenta-announces-fiscal-2026-third-quarter-conference-call-and-webcast-48419fff)
- 2026-07-22 20:05 EST — VKTX — [Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f)
- 2026-07-22 20:01 EST — AXON — [Axon to Release Second Quarter 2026 Earnings on August 5, 2026](https://biopharmsignal.com/news/AXON/axon-to-release-second-quarter-2026-earnings-on-august-5-2026-66120902)
- 2026-07-22 12:39 EST — ARTL — [New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition](https://biopharmsignal.com/news/ARTL/new-analysis-of-over-50-studies-showed-that-all-the-non-prescription-cbd-product-a3445432)